1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Boston Scientific’s Synergy Stent Narrowly Outperforms Biosensors’ Biomatrix NeoFlex In Danish Study

 
• By Reed Miller

Data from the 2,770-patient randomized SORT OUT VIII trial showed Boston Scientific’s Synergy everolimus-eluting stent is noninferior to Biosensor’s Biomatrix NeoFlex Biolimus-eluting stent for the endpoint of target lesion failure, but the procedure failure-rate was lower in the Synergy patients, which may have led to lower overall rates of myocardial infarction.

Synergy by Boston Science
Synergy thin-strut biodegradable-polymer everolimus-eluting platinum-chromium stent • Source: Boston Scientific

[Editor's note: Complete historical information on important medical device trial announcements is available from Informa’s MedDeviceTracker. Click here to request a demonstration. For an archive of previous Medtech Insight articles on medtech clinical trials, visit the Tracking Trials page.]

One-year results from SORT OUT VIII, a randomized trial comparing two metal drug-eluting coronary stents with biodegradeable polymers, demonstrate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

CorTec Begins First Human Trial Of Wireless Brain Implant For Stroke Rehab

 
• By Marion Webb

Germany’s CorTec has implanted its wireless brain-computer interface in a stroke patient, launching a trial to test safety and whether brain stimulation during physical therapy can help restore movement where traditional rehab has failed.

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 
• By Brian Bossetta

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

Abbott Lowers Outlook But Headwinds Are Temporary

 
• By Natasha Barrow

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.

More from R&D

FDA ‘Regulatory Accelerator’ Aims To Speed Digital Health Development

 
• By Elizabeth Orr

The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.

Opinion: Catch A Fraudulent Scientist -- If You Can

 
• By Ivor Campbell

As AI tools make research fraud and résumé fraud easier than ever, life sciences companies need to take steps to protect themselves. Snedden Campbell CEO Ivor Campbell has some tips on successful strategies.

Rising Oncology Start-ups Recognized For Breakthrough Cancer Research

 
• By Natasha Barrow

The Cancer Research Horizons Innovation Awards took place on July 10. Medtech Insight spoke to nominees for the women’s entrepreneur of the year award: Mireia Crispin-Ortuzar, CEO of 52 North Health; Anita Grigoriadis, CEO of PharosAI; and Maria Giovanna Lizio, Founder of WILD-Imaging Technology.